| Literature DB >> 36091444 |
Xinyu Xiong1, Li Wang2,3, Shan He1, Shanyue Guan2, Dawei Li4, Mingming Zhang5, Xiaozhong Qu3.
Abstract
Phototherapy and multimodal synergistic phototherapy (including synergistic photothermal and photodynamic therapy as well as combined phototherapy and other therapies) are promising to achieve accurate diagnosis and efficient treatment for tumor, providing a novel opportunity to overcome cancer. Notably, various nanomaterials have made significant contributions to phototherapy through both improving therapeutic efficiency and reducing side effects. The most key factor affecting the performance of phototherapeutic nanomaterials is their microstructure which in principle determines their physicochemical properties and the resulting phototherapeutic efficiency. Vacancy defects ubiquitously existing in phototherapeutic nanomaterials have a great influence on their microstructure, and constructing and regulating vacancy defect in phototherapeutic nanomaterials is an essential and effective strategy for modulating their microstructure and improving their phototherapeutic efficacy. Thus, this inspires growing research interest in vacancy engineering strategies and vacancy-engineered nanomaterials for phototherapy. In this review, we summarize the understanding, construction, and application of vacancy defects in phototherapeutic nanomaterials. Starting from the perspective of defect chemistry and engineering, we also review the types, structural features, and properties of vacancy defects in phototherapeutic nanomaterials. Finally, we focus on the representative vacancy defective nanomaterials recently developed through vacancy engineering for phototherapy, and discuss the significant influence and role of vacancy defects on phototherapy and multimodal synergistic phototherapy. Therefore, we sincerely hope that this review can provide a profound understanding and inspiration for the design of advanced phototherapeutic nanomaterials, and significantly promote the development of the efficient therapies against tumor.Entities:
Keywords: microstructure; multimodal synergistic phototherapy; nanophotosensitizers; phototherapy; vacancy defect engineering
Year: 2022 PMID: 36091444 PMCID: PMC9452887 DOI: 10.3389/fbioe.2022.972837
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
SCHEME 1Schematic illustration of vacancy defect-promoted nanomaterials for efficient phototherapy and multimodal synergistic phototherapy.
FIGURE 1(A) Schematic of various defects in crystals. Reproduced with permission from Xie et al. (2020). Copyright © 2020 American Chemical Society. (B) Illustrations of O2 adsorption on partially reduced TiO2 surface to form •O2 − (adsorbed type A) and O2 adsorption on oxygen vacancy defective TiO2 surface to form •O2 − under light irradiation (adsorbed type B). Reproduced with permission from Komaguchi et al. (2010). Copyright © 2010 American Chemical Society. (C) Schematic density of states for TiO2 P25 Degussa (black dotted line) and black TiO2 nanoparticle with oxygen vacancies (red line), Vo represents the localized states created by oxygen vacancies in black TiO2 nanoparticle; illustration of the microstructure of black TiO2 nanoparticle with oxygen vacancies, Vo represents the oxygen vacancy. Reproduced with permission from Naldoni et al. (2012). Copyright © 2012 American Chemical Society. (D) NIR spectra of Cu vacancy defective Cu2−xS. Reproduced with permission from Zhao et al. (2009). Copyright © 2009 American Chemical Society.
FIGURE 2(A) Schematic illustration of the preparation of ultrathin MnO2 nanosheets with abundant oxygen vacancies through hydrothermal method. Reproduced with permission from Wang L. et al. (2019). Copyright © 2019 American Chemical Society. (B) Illustration of the formation process of oxygen vacancies in Ce-doped Aurivillius Bi2MoO6 structure. Reproduced with permission from Dai et al. (2016). Copyright © 2016 American Chemical Society.
Summary of the vacancy defective nanomaterials for phototherapy and multimodal synergistic phototherapy from recent reports in the literature.
| Nanomaterials | Vacancy defect type | Methods | Irradiation wavelength (nm) | Irradiation power density (W cm−2) | Therapeutic modality | Imaging mode | Cell lines | References |
|---|---|---|---|---|---|---|---|---|
| Ultrathin MnO2 nanosheets | Oxygen vacancy | Hydrothermal method | 808 | 1.0 | PTT | PAI, MAI, and thermal imaging | HeLa cells |
|
| PEG-Na
| Oxygen vacancy | Chemical mixing procedure at different temperatures and subsequent thermal decomposition | 980 | 1.5 | PTT | MAI and thermal imaging | 4T1 cells |
|
| Na
| Oxygen vacancy | Chemical mixing procedure at different temperatures and subsequent thermal decomposition | 980 | 1.0 | PTT | Thermal imaging, PAI, and MRI | 4T1 cells |
|
| ]MoO3− | Oxygen vacancy | Hydrothermal method, followed by ball milling process and lithium treatment | 1,064 | 0.75 | PTT | PAI and thermal imaging | 4T1 cells |
|
| BiOBr−H/Rub2d nanocomposites | Oxygen vacancy | Hydrothermal method and subsequent heat treatment | 520 | 10.0 | PDT | FLI | HeLa cells |
|
| CaAl2O4:Eu, Nd (CAO) nanosheets | Oxygen vacancy | Combination of high temperature solid state reaction and subsequent wet-grinding and ultrasound treatment | Pre-excitation with 365 nm UV lamp and re-excitation with white LED | -- | Self-illuminating PDT | -- | 4T1 cells |
|
| B-TiO2− | Oxygen vacancy | Mg-thermic reduction of TiO2 | 808 | 0.48 | Synergistic PTT/PDT | Thermal imaging | B16F10 melanoma cells |
|
| ZrO2− | Oxygen vacancy | Magnesium reduction procedure and subsequent surface modification | 660 and 808 | 0.76 for 660 nm and 2.0 for 808 nm | Synergistic PTT/PDT | FLI and PAI | 4T1 cells |
|
| PEG-MoO
| Oxygen vacancy | Hydrothermal method | 808 and 1,064 | 0.75 for 808 nm and 0.6 for 1,064 nm | Synergistic PTT/PDT | Thermal imaging | HeLa cells |
|
| TiO2@red phosphorus nanorods | Oxygen vacancy | Vaporization-deposition method | 808 | 0.85 | Synergistic PTT/PDT | Thermal imaging | ccRCC cells |
|
| CaO-SiO2-TiO2 (CST) nanocomposites | Oxygen vacancy | Containerless melting technology | 808 | 0.8 W cm−2 and 1 W cm−2 for NIR irradiation; 10.0 W cm−2 for xenon lamp irradiation | Synergistic PTT/PDT | Thermal imaging | LM8 cells |
|
| MnO2@Au nanoconstructs | Oxygen vacancy | One-step reduction method | 808 | 1.0 | Synergistic PTT/CDT | Thermal imaging | HeLa cells |
|
| NH−MoO3− | Oxygen vacancy | Hydrothermal method, followed by ball milling process, co-intercalation, and surface modification | 1,064 | 0.8 | Synergistic PTT/CDT | Thermal imaging | HUVE, HeLa, 4T1 cells |
|
| O | Oxygen vacancy | Chemical mixing procedure at different temperatures | 1,064 | 1.0 | Synergistic PTT/CDT | Thermal imaging and PAI | 4T1 and HL-7702 cells |
|
| Black mica (BM) nanosheets | Oxygen vacancy | Combination of calcination, n-butyllithium exchange and intercalation, and liquid exfoliating processes | 650 and 808 | 0.5 for 650 nm and 1.0 for 808 nm | Synergistic PTT/PDT/CDT | FLI, PAI, and thermal imaging | A549, Hela, MCF7, and PC3 cells |
|
| d-Cu-LDH/ICG nanoparticles | Oxygen vacancy | Coprecipitation method, followed by isomorphic substitution and acid etching | 808 | 0.23 and 0.5 | Synergistic PTT/PDT/CDT | FLI | 4T1 cells |
|
| Functional core layers (FLCs) nanosheets | Oxygen vacancy | Wet-chemical exfoliation method based on alkali etching | 658 and 808 | 0.5 for 658 nm and 1.0 for 808 nm | Synergistic PTT/PDT/CDT | FLI, PAI, and thermal imaging | A549, HepG2, CCD-25Lu, HEK 293, and THLE-3 cells |
|
| As/As
| Oxygen vacancy | Coupling ball-grinding with probe sonication-based liquid exfoliating processes and subsequent surface modification | 660 and 808 | 0.3 for 660 nm and 1.0 for 808 nm | Synergistic PTT/PDT/CDT | FLI | A549 and MCF-7 cells |
|
| WB@hydrogel | Oxygen vacancy | Hydrothermal method and subsequent hydrogenation reaction | 1,064 | 1.5 | Synergistic PTT/GT | FLI | 4T1 and HepG2 cells |
|
| ZrO2− | Oxygen vacancy | Modified magnesium (Mg) reduction process | 1,064 | 1.0 | Synergistic PTT/SDT | PAI, and thermal imaging | 4T1 cells |
|
| TiO2@TiO2− | Oxygen vacancy | Aluminum (Al) reduction procedure | 1,064 | 1.5 | Synergistic PTT/SDT | Thermal imaging | 4T1 cells |
|
| Bi2S3-Au nanorods | Sulfur vacancy | Solvothermal method and subsequent | 808 | 0.9 | PTT | CT and thermal imaging | 4T1 cells |
|
| FeS2 nanoparticles | Sulfur vacancy | Solvothermal method | 915 | 1.0 | PTT | Ultrasound imaging, thermal imaging, and MRI | SMMC-7721 cells |
|
| Bi2Se3 nanodots | Selenium vacancy | Scalable biomineralization approach | 1,064 | 1.4 | PTT | CT, PAI, and thermal imaging | 4T1 cells |
|
| PTh@Au nanoconstructs | Sulfur vacancy | One-step redox strategy | 650 | 50.0 | PDT | -- | HeLa and U14 cells |
|
| MoS2 quantum dots | Sulfur vacancy | Aqueous room temperature bottom-up synthesis | 400–800 | 10.0 | PDT | -- | SW480 cells |
|
| Fe3S4 tetragonal nanosheets | Sulfur vacancy | Hot-injection thermal decomposition reaction and subsequent surface modification | 915 | 0.5 | Synergistic PTT/PDT | Thermal imaging, and MRI | HeLa cells |
|
| T80-AuPt@CuS nanosheets | Sulfur vacancy |
| 808 | 1.0 | Synergistic PTT/radiotherapy | CT and PAI | 4T1 cells |
|
| Cu2− | Cu vacancy | Aqueous reduction process and subsequent surface modification | 808 | 1.5 | PTT | PAI, CT, SPECT, and thermal imaging | 4T1 cells |
|
| Ultrathin CuS nanocrystals | Cu vacancy | Microwave-assisted synthesis strategy | 980 | 2.48 | PTT | FLI | PC-3/Luc+ cells |
|
| Cu3BiS3 nanocrystals | Cu vacancy | Solvothermal method | 915 | 1.2 | PTT | CT and thermal imaging | TC71 cells |
|
| Au@Cu2− | Cu vacancy | Nonepitaxial strategy of tributylphosphine-initialized cation exchange | 808 and 1,064 | 1.0 for 808 nm and 0.7 for 1,064 nm | PTT | -- | HeLa cells |
|
| Ultrasmall Cu2− | Cu vacancy | One-step redox strategy and subsequent surface modification | 1,064 | 1.5 | Synergistic PTT/CDT | PAI and thermal imaging | 4T1 cells |
|
| CoCuFeSe-PVP-L-Arg nanosheets | Cu vacancy |
| 808 | 1.0 | Synergistic PTT/GT | PAI, thermal imaging, and FLI | HepG2 and 4T1 cells |
|
| Pt–CuS–PNTs nanocomposite | Cu vacancy | Co-assembly, followed by biomineralization process and covalent graft | 808 | 0.5 | Synergistic PTT/PDT/chemotherapy | Thermal imaging | B16-F10 cells |
|
| MoSe2/Bi2Se3@PEG-Dox nanocomposites | Mo vacancy | Ultrasound-assisted exfoliated method and subsequent cation exchange method | 808 | 0.2, 0.5, and 1.0 | Synergistic PTT/PDT/chemotherapy | Thermal imaging, PAI, and CT | L02 and HepG2 cells |
|
| CoFe-mixed metal oxide (CoFe- | Co vacancy | Heat treatment of LDHs precursor | 808 | 1.0 | PTT | PAI and MRI | HeLa cells |
|
| W1.33C-BSA nanosheets | W vacancy | Solid state sintering, followed by acid etching, exfoliation treatment, and surface modification | 808 and 1,064 | 1.25 | PTT | PAI, FLI, CT, and thermal imaging | 4T1 and L929 cells |
|
| 5-FU/Cu-LDH nanoparticles | Mg and OH vacancy | Hydrothermal Method, followed by intercalation treatment and acid etching | 808 | 1.0 | PTT | MRI and thermal imaging | HCT-116 cells |
|
| Ag@Ag2O/LDHs-U nanocomposites | Ag and oxygen vacancy | Modified solvent-free bottom-up approach, followed by | 1,064 | 1.0 | PTT | FLI and PAI | L02, HeLa, and HepG2 cells |
|
| Cu@CPP-t nanoparticles | Carbon vacancy | Pyrolysis of Cu-BTC precursor | 808 | 1.6 | PTT | PAI and thermal imaging | Hela cells |
|
| Graphene quantum dots | Carbon vacancy | Magnetic field-assisted solvothermal method | 1,064 | 1.0 | PTT | Thermal imaging | 4T1, Hela, and H196 cells |
|
| B4C@C nanosheets | Carbon vacancy | Hydrothermal method | 1,064 | 1.0 | PTT | PAI and FLI | HeLa and HepG2 cells |
|
| Pd nanozyme | Carbon vacancy | Pyrolysis of Pd@ZIF-8 precursor | 1,064 | 0.28 | Synergistic PTT/CDT | -- | L929 and 4T1 cells |
|
| C/Mo2C@MoO
| Carbon vacancy | Pyrolysis of Mo/ZIF-8 precursor | 1,064 | 1.0 | Synergistic PTT/CDT | PAI and FLI | L02 and HeLa cells |
|
FIGURE 3(A) Schematic diagram of NaxGdWO3 nanorods for MRI-guided photothermal, TEM images of NaxGdWO3 nanorods, and in vivo T 1-weighted MR images of 4T1-tumor-bearing mice before and after (I)T. injection of NaxGdWO3 nanorods. Reproduced with permission from Ni et al. (2017). Copyright © 2017 American Chemical Society. (B) Schematic illustration of geometric structure of various BiOBr-based samples and Rub2d sample, band structures of BiOBr and BiOBr–H, and the band edge positions of BiOBr, BiOBr–H and Rub2d. Reproduced with permission from Guan et al. (2019). Copyright © 2019 The Royal Society of Chemistry.
FIGURE 4Illustration on action mechanism of B-TiO2−x for synergetic PTT and PDT, geometric-phase analysis (GPA) of B-TiO2−x (white arrows indicate the position of atomic dislocations), calcein AM and PI co-staining of B16F10 melanoma cells after the treatment with B-TiO2−x and NIR irradiation, infrared thermal images of B16F10 tumor-bearing mice after various treatments, and representative photographs of the dissected tumors. Reproduced with permission from Wang X. et al. (2019). Copyright © 2019 American Chemical Society.
FIGURE 5STEM image of AuPt@CuS NSs, schematic illustration of enhanced photothermal mechanism of AuPt@CuS NSs, proposed mechanism of the enhanced deposition of radiation energy by AuPt@CuS NSs, tumor growth curves of 4T1 tumor-bearing mice after various treatments, representative photographs of the dissected tumors, and evaluation of dual modal CT/PA bioimaging capability of T80-AuPt@CuS NSs. Reproduced with permission from Cai et al. (2021). Copyright © 2021 American Chemical Society.
FIGURE 6Schematic Illustration of the synthesis of CoFe-500 for PA/MR/NIR imaging-guided PTT, Fourier-transform EXAFS spectra at Co K-edge for various CoFe-x samples, Co 2p XPS spectra for CoFe-500 and CoFe-800, Co2+ defect/Co2+ peak area ratio for various CoFe-x samples, and optimized geometries for a CoFe-500 bulk heterojunction composed of CoO-VCo and CoFe2O4-VCo, band structures of CoO-VCo and CoFe2O4-VCo, 3D PAI images of tumor site at 6 h postinjection, in vivo T1-MRI imaging of HeLa-bearing mice before and after injected with CoFe-500, and photographs at different times after various treatments. Reproduced with permission from Wang L. et al. (2021). Copyright © 2020 American Chemical Society.